Marc Beer

Page breadcrumbsEnd of page breadcrumbs

Renovia’s CEO Marc Beer Raises Over $40 Million in Funding and Debt Venture

 

Marc Beer, the CEO of Renovia has 25 plus years of expertise in the biotechnology, diagnostics, and pharmaceutical industries. Gazette reported the beginning of October 2018 that he raised $32 million in funds and $10 million in venture debt for his new start-up company. He started the company with Ramon Iglesias and Yolanda Lorie as a medical technology entity, in 2016. Their mission is to develop diagnostic and treatment products for women diagnosed with pelvic disorders. Throughout his career, he’s started successful businesses and serves on the board of directors for companies and educational institutions.

 

When Beer started Renovia, he received his first round of funding from healthcare investment group, Longwood Fund. With the help of Perceptive Advisers and Ascension Ventures, he raised the second round of funding to support four of their products. In April of this year, the FDA approved a new product, Leva produced by the company. Marc told Gazette he now can improve the diagnosis and treatment for women diagnosed with the pelvic disorder. He plans to lead the development with the combination of proprietary technologies and a digital health forum.

 

The technologies and forum will provide educational and informative information that produces treatment options to customers. The goal is to increase understanding of the disorder that will eventually lead to reducing health care costs long term. Marc Beer explains that they designed treatments to restore pelvic health using various solutions to strengthen the muscles. He says Renovia plans to create a new generation of Leva for patients suffering from urinary contingency disorders. Pelvic floor disorder effects 250 million women and is treatable with the proper products.

 

Before co-finding Renovia, Marc Beer found ViaCell, a biotechnology company specializing in the development, preservation, and collection of blood stem cells. He started the business in 2000 and experienced rapid growth within seven years. By 2005, ViaCell became a public traded enterprise with 300 workers. Beer held positions with Global Marketing, Genzyme, Abbott Laboratories, Erytech Pharma, Good Start Genetics, Minerva Neurosciences, and Commonwealth of Massachusetts. His executive titles include vice president, board member director, chief executive officer, and chairman.

 

Marc is a Miami University graduate earning a BA in Business Science, in 1987. He has over 25 years of experience in development and commercialization in the devices, diagnostics, pharmaceutical, and biotechnology fields. While serving on the board of directors for a cancer foundation, he helped many cancer patients and their families during difficult times. Beer serves as a member of the Miami University Business Advisory Council. He served on the Graduate Studies Research and Advisory Council and the Research and Commercialization Advisory Committee at Notre Dame. Learn more: https://www1.salary.com/Marc-Beer-Salary-Bonus-Stock-Options-for-AEGERION-PHARMACEUTICALS-INC.html